These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38791945)
1. Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway. Luvero D; Cundari GB; Ficarola F; Plotti F; Terranova C; Montera R; Bogani G; Silvagni A; Celoro F; Angioli R Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791945 [TBL] [Abstract][Full Text] [Related]
2. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H). Liao Y; Zhu C; Song X; Ruan J; Ding Y; Chen Y; Yang Q Med Sci Monit; 2022 Mar; 28():e934493. PubMed ID: 35322001 [TBL] [Abstract][Full Text] [Related]
4. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009 [No Abstract] [Full Text] [Related]
5. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience. Tuninetti V; Pace L; Ghisoni E; Quarà V; Arezzo F; Palicelli A; Mandato VD; Geuna E; Cormio G; Biglia N; Borsotti L; Gallo S; Ferrero A; Jacomuzzi E; Fuso L; Pezua Sanjinez JOS; Puppo A; Caglio A; Rognone C; Turinetto M; Scotto G; Di Maio M; Valabrega G Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509300 [TBL] [Abstract][Full Text] [Related]
6. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923 [TBL] [Abstract][Full Text] [Related]
7. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis. Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895 [TBL] [Abstract][Full Text] [Related]
8. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649 [TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107 [TBL] [Abstract][Full Text] [Related]
11. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267 [TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222 [TBL] [Abstract][Full Text] [Related]
13. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab. El-Ghazzi N; Durando X; Giro A; Herrmann T Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208 [TBL] [Abstract][Full Text] [Related]
15. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer. Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P Cells; 2021 Jul; 10(8):. PubMed ID: 34440647 [TBL] [Abstract][Full Text] [Related]
17. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494 [TBL] [Abstract][Full Text] [Related]
18. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576 [TBL] [Abstract][Full Text] [Related]
19. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer. Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D PeerJ; 2023; 11():e15920. PubMed ID: 37663290 [TBL] [Abstract][Full Text] [Related]
20. The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis. Kok PS; Antill YC; Scott CL; Lee CK ESMO Open; 2022 Dec; 7(6):100635. PubMed ID: 36410086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]